Emerald Health Therapeutics’ Joint Venture Pure Sunfarms Launches Branded Product Line, Introducing Eight Products for the ...
17 September 2019 - 7:00AM
Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX:
EMHTF), today announced that its 50%-owned joint venture for
large-scale, low-cost, high-quality cannabis production, Pure
Sunfarms (PSF), has formally launched its Pure Sunfarms branded
products and introduced eight strains of dried cannabis flower for
the Canadian recreational market. It has also begun shipping
branded dried cannabis products to the Ontario Cannabis Store
(“OCS”) for retail sale in Ontario. PSF expects its first products
to be available at licensed retailers in Ontario and through the
OCS website this month.
“Introducing the Pure Sunfarms brand today to
Canadians is a culmination of our team’s efforts, and we hope
consumers see the passion and care our people have worked hard to
bring to life,” said Mandesh Dosanjh, President and CEO, Pure
Sunfarms. “British Columbia has a reputation for growing some of
the best cannabis in the world, and we are proud to introduce a
suite of products which will continue to celebrate this legacy. Our
scale, along with the team’s deep agricultural roots and steadfast
dedication to craftmanship, has allowed us to cultivate
great-quality products at an approachable price point. In this
evolving industry, we hope Canadians will come to know the quality
and consistency of Pure Sunfarms’ products and love it as much as
we do.”
The Pure Sunfarms brand was built around the
philosophy of ‘plants and people first,’ expressing a long-standing
relationship and deep appreciation for cannabis across Canada’s
west coast. It was designed to reflect the team’s unique and
diverse agricultural experience, sharing the story of cannabis from
a different perspective. This new brand effectively leverages its
high-quality product with Pure Sunfarms’ low-cost production
capability. “Bringing its first selection of branded products to
the recreational market represents another important milestone for
Pure Sunfarms,” said Riaz Bandali, CEO of Emerald. “Given Pure
Sunfarms’ expected full run-rate production to expand to 150,000
kilograms by the end of next year, and now with the rollout of its
brand strategy, PSF is well-positioned to bring to market cannabis
products with higher margin sales that meet the needs of
consumers.”In addition to Ontario, Pure Sunfarms expects its first
products to be available at licensed retailers and online in
British Columbia in the coming weeks.More information is available
on Pure Sunfarms’ new website at www.puresunfarms.com.
About Emerald Health Therapeutics,
Inc. Emerald Health Therapeutics, Inc. is a Canadian
licensed producer of cannabis products, with strategic initiatives
focused on differentiated, value-added product development for
medical and adult-use customers supported by novel intellectual
property, large-scale cultivation, extraction, and soft gel
encapsulation, as well as unique marketing and distribution
channels. Its 50%-owned Pure Sunfarms operation in British Columbia
has reached its full run-rate annual production of approximately
75,000 kg in its first 1.1 million square-foot greenhouse Delta 3
operation; its second 1.1 million square-foot greenhouse is planned
to be in full production by the end of 2020. Emerald’s two
wholly-owned facilities in Quebec, a high-quality indoor growing
and processing facility, and in British Columbia, an organic
greenhouse and outdoor operation, are completing construction and
are working toward final licensing extension. Emerald has also
contracted for approximately 1,000 acres of hemp annually in 2019
to 2022 with the objective of extracting low-cost CBD. Its team is
highly experienced in life sciences, product development,
large-scale agri-business, and marketing.
For more information or contact: Rob Hill, Chief Financial
Officer (800) 757 3536 Ext. # 5
Emerald Investor Relations (800) 757 3536 Ext.
#5invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements. Such statements
include obtaining required regulatory approvals; production and
processing capacity of various facilities; expansion of facilities;
obtaining additional cultivation licenses and other permits;
production at various facilities; receipt of hemp deliveries;
entering into of strategic agreements; payments of amounts owed to
and owed by Emerald; transplanting crops; obtaining final municipal
approvals; assessment of cultivation and harvesting techniques;
scale up of reliable, quality low-cost cannabis; and anticipated
production costs.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, changes of law and regulations; changes of
government; failure to obtain regulatory approvals or permits;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; failure of counter-parties to perform
contractual obligations; as well as the risk factors described in
the Company’s annual information form and other regulatory filings.
The forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. The Company
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Jan 2025 to Feb 2025
Emerald Health Therapeut... (TSXV:EMH)
Historical Stock Chart
From Feb 2024 to Feb 2025